[go: up one dir, main page]

CY2019030I2 - Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα - Google Patents

Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα

Info

Publication number
CY2019030I2
CY2019030I2 CY2019030C CY2019030C CY2019030I2 CY 2019030 I2 CY2019030 I2 CY 2019030I2 CY 2019030 C CY2019030 C CY 2019030C CY 2019030 C CY2019030 C CY 2019030C CY 2019030 I2 CY2019030 I2 CY 2019030I2
Authority
CY
Cyprus
Prior art keywords
lung cancer
therapeutic treatment
rapamycin derivative
rapamycin
derivative
Prior art date
Application number
CY2019030C
Other languages
English (en)
Other versions
CY2019030I1 (el
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26245731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2019030(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0104072A external-priority patent/GB0104072D0/en
Priority claimed from GB0124957A external-priority patent/GB0124957D0/en
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of CY2019030I2 publication Critical patent/CY2019030I2/el
Publication of CY2019030I1 publication Critical patent/CY2019030I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
CY2019030C 2001-02-19 2019-06-04 Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα CY2019030I1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0104072A GB0104072D0 (en) 2001-02-19 2001-02-19 Organic compounds
GB0124957A GB0124957D0 (en) 2001-10-17 2001-10-17 Organic compounds
EP02719864A EP1363627A2 (en) 2001-02-19 2002-02-18 Treatment of solid tumours with rapamycin derivatives
PCT/EP2002/001714 WO2002066019A2 (en) 2001-02-19 2002-02-18 Cancer treatment
EP14164259.5A EP2783686B1 (en) 2001-02-19 2002-02-18 Combination of a rapamycin derivative and letrozole for treating breast cancer

Publications (2)

Publication Number Publication Date
CY2019030I2 true CY2019030I2 (el) 2020-05-29
CY2019030I1 CY2019030I1 (el) 2020-05-29

Family

ID=26245731

Family Applications (11)

Application Number Title Priority Date Filing Date
CY20151100711T CY1116616T1 (el) 2001-02-19 2015-08-13 Θεραπευτικη αγωγη ογκων του μαστου με παραγωγο ραπαμυκινης σε συνδυασμο με εξεμεστανη
CY2015044C CY2015044I1 (el) 2001-02-19 2015-11-19 Θεραπευτικη αγωγη ογκων του μαστου με παραγωγο ραπαμυκινης σε συνδυασμο με εξεμεστανη
CY20161101060T CY1118316T1 (el) 2001-02-19 2016-10-21 Θεραπεια συμπαγων νεφρικων ογκων με ενα παραγωγο ραπαμυκινης
CY2016047C CY2016047I1 (el) 2001-02-19 2016-12-20 Θεραπεια συμπαγων νεφρικων ογκων με ενα παραγωγο ραπαμυκινης
CY20171100668T CY1119029T1 (el) 2001-02-19 2017-06-22 Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης
CY20191100021T CY1121314T1 (el) 2001-02-19 2019-01-10 Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
CY2019030C CY2019030I1 (el) 2001-02-19 2019-06-04 Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
CY20191100619T CY1121715T1 (el) 2001-02-19 2019-06-14 Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση συμπαγους νεοπλασιας που σχετιζεται με την απορυθμισμενη αγγειογενεση
CY20191100925T CY1121983T1 (el) 2001-02-19 2019-09-03 Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση καρκινου του παγκρεατος
CY2019043C CY2019043I1 (el) 2001-02-19 2019-11-21 Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση συμπαγους νεοπλασιας που σχετιζεται με την απορυθμισμενη αγγειογενεση
CY2020005C CY2020005I1 (el) 2001-02-19 2020-02-20 Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση καρκινου του παγκρεατος

Family Applications Before (6)

Application Number Title Priority Date Filing Date
CY20151100711T CY1116616T1 (el) 2001-02-19 2015-08-13 Θεραπευτικη αγωγη ογκων του μαστου με παραγωγο ραπαμυκινης σε συνδυασμο με εξεμεστανη
CY2015044C CY2015044I1 (el) 2001-02-19 2015-11-19 Θεραπευτικη αγωγη ογκων του μαστου με παραγωγο ραπαμυκινης σε συνδυασμο με εξεμεστανη
CY20161101060T CY1118316T1 (el) 2001-02-19 2016-10-21 Θεραπεια συμπαγων νεφρικων ογκων με ενα παραγωγο ραπαμυκινης
CY2016047C CY2016047I1 (el) 2001-02-19 2016-12-20 Θεραπεια συμπαγων νεφρικων ογκων με ενα παραγωγο ραπαμυκινης
CY20171100668T CY1119029T1 (el) 2001-02-19 2017-06-22 Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης
CY20191100021T CY1121314T1 (el) 2001-02-19 2019-01-10 Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα

Family Applications After (4)

Application Number Title Priority Date Filing Date
CY20191100619T CY1121715T1 (el) 2001-02-19 2019-06-14 Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση συμπαγους νεοπλασιας που σχετιζεται με την απορυθμισμενη αγγειογενεση
CY20191100925T CY1121983T1 (el) 2001-02-19 2019-09-03 Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση καρκινου του παγκρεατος
CY2019043C CY2019043I1 (el) 2001-02-19 2019-11-21 Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση συμπαγους νεοπλασιας που σχετιζεται με την απορυθμισμενη αγγειογενεση
CY2020005C CY2020005I1 (el) 2001-02-19 2020-02-20 Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση καρκινου του παγκρεατος

Country Status (27)

Country Link
US (10) US8410131B2 (el)
EP (11) EP3351246B8 (el)
JP (14) JP2004525899A (el)
KR (3) KR20050095906A (el)
CN (5) CN104116738A (el)
AU (1) AU2002250968C1 (el)
BR (1) BR0207378A (el)
CA (3) CA2860306C (el)
CY (11) CY1116616T1 (el)
CZ (5) CZ303611B6 (el)
DK (6) DK2269604T3 (el)
ES (8) ES2600304T3 (el)
HK (2) HK1250336B (el)
HU (1) HUP0303271A3 (el)
IL (13) IL157425A0 (el)
LT (9) LT2762140T (el)
LU (3) LU92880I2 (el)
MX (3) MX368013B (el)
NO (14) NO333105B1 (el)
NZ (1) NZ527692A (el)
PL (5) PL414997A1 (el)
PT (7) PT3143995T (el)
RU (8) RU2322981C2 (el)
SI (6) SI2269604T1 (el)
SK (5) SK288546B6 (el)
TW (2) TWI334350B (el)
WO (1) WO2002066019A2 (el)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2002250968C1 (en) 2001-02-19 2018-01-04 Novartis Ag Cancer treatment
MXPA03010907A (es) * 2001-06-01 2004-02-17 Wyeth Corp Combinaciones antineoplasicas.
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
PT1545553E (pt) 2002-07-30 2011-09-12 Aeterna Zentaris Gmbh Utilização de alquilfosfocolinas em combinação com medicamentos antitumorais
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
US7846141B2 (en) 2002-09-03 2010-12-07 Bluesky Medical Group Incorporated Reduced pressure treatment system
BR0314555A (pt) * 2002-10-11 2005-08-09 Dana Farber Cancer Inst Inc Derivados de epotilona para o tratamento de mieloma múltiplo
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
WO2005080593A2 (en) * 2004-02-23 2005-09-01 Novartis Ag P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent
WO2005092384A2 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy with azd2171 and a platinum anti-tumour agent
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
KR101492584B1 (ko) 2005-02-09 2015-02-11 산텐 세이야꾸 가부시키가이샤 질환 또는 상태의 치료를 위한 액체 제제
DK2388315T3 (da) * 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
BRPI0613692A2 (pt) * 2005-07-20 2011-01-25 Novartis Ag combinação farmacêutica e uso da mesma
WO2007059106A2 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
NO20220050A1 (no) * 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
JP5639743B2 (ja) 2006-02-02 2014-12-10 ノバルティス アーゲー 結節性硬化症処置
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
AU2007240548A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
CA2661024A1 (en) * 2006-08-28 2008-03-06 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
US9820888B2 (en) 2006-09-26 2017-11-21 Smith & Nephew, Inc. Wound dressing
EP2481402B1 (en) * 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101292980B (zh) * 2007-04-28 2010-11-10 上海交通大学医学院附属仁济医院 一种含有雷帕霉素的用于治疗大肠癌的药物组合物
ES2706023T3 (es) * 2007-08-16 2019-03-27 Biocompatibles Uk Ltd Administración de combinaciones de fármacos
WO2009058895A1 (en) * 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
US8298200B2 (en) 2009-06-01 2012-10-30 Tyco Healthcare Group Lp System for providing continual drainage in negative pressure wound therapy
US20120040896A1 (en) * 2008-04-11 2012-02-16 The Regents Of The University Of Colorado Compositions, methods and uses for modulation of brca 1
CN102171343B (zh) * 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
GB0902368D0 (en) 2009-02-13 2009-04-01 Smith & Nephew Wound packing
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
US8791315B2 (en) 2010-02-26 2014-07-29 Smith & Nephew, Inc. Systems and methods for using negative pressure wound therapy to manage open abdominal wounds
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
CN105037552B (zh) 2010-08-20 2019-03-29 诺华股份有限公司 表皮生长因子受体3（her3)的抗体
KR102218497B1 (ko) * 2011-12-05 2021-02-22 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
BR112014029100A2 (pt) 2012-05-23 2017-06-27 Smith & Nephew aparelhos e métodos para terapia de ferida por pressão negativa
EP4112020B1 (en) 2012-08-01 2025-12-10 Smith & Nephew plc Wound dressing and method of treatment
HUE033329T2 (en) 2012-08-01 2017-11-28 Smith & Nephew dressing
BR112015020855A2 (pt) 2013-03-15 2017-07-18 Smith & Nephew curativo para ferida e método de tratamento
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
JP6623745B2 (ja) * 2015-06-29 2019-12-25 富士通株式会社 電子回路及び発振器の制御方法
PL3640345T3 (pl) * 2015-08-17 2022-02-07 Kura Oncology, Inc. Sposoby leczenia pacjentów z nowotworem z użyciem inhibitorów farnezylotransferazy
JP2019508443A (ja) * 2016-03-15 2019-03-28 タイム，インコーポレーテッド 癌の処置のための医薬組成物
EP3548894B1 (en) 2016-12-02 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing renal cell carcinoma
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3644914A1 (en) 2017-06-30 2020-05-06 T J Smith & Nephew Limited Negative pressure wound therapy apparatus
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
WO2019089556A1 (en) * 2017-10-31 2019-05-09 Steve Gorlin Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof
WO2019139921A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
HRP20230488T1 (hr) 2018-05-01 2023-08-04 Revolution Medicines, Inc. C40-, C28- I C-32-VEZANI ANALOZI RAPAMICINA KAO INHIBITORI mTOR
AU2019262979B2 (en) 2018-05-01 2023-07-06 Revolution Medicines, Inc. C26-linked rapamycin analogs as mTOR inhibitors
CN108825638A (zh) * 2018-08-01 2018-11-16 安徽送变电工程有限公司 一种应用于螺纹工件的防盗装置
MX2021007247A (es) 2018-12-18 2021-07-15 Novartis Ag Derivados de rapamicina.
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
EA202193111A1 (ru) 2019-05-14 2022-02-10 Тайм, Инк. Композиции и способы для лечения рака
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
KR20230053539A (ko) 2021-10-14 2023-04-21 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물
IL317056A (en) 2022-05-18 2025-01-01 Hadasit Med Res Service Combining endocannabinoid and MTOR inhibitors in the treatment of neuroendocrine tumors
TW202402277A (zh) 2022-05-25 2024-01-16 美商銳新醫藥公司 以mtor抑制劑治療癌症之方法

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US876165A (en) 1904-05-11 1908-01-07 George K Woodworth Wireless telegraph transmitting system.
GB104072A (en) 1916-04-14 1917-02-22 William Henry Nosworthy Apparatus for Lighting Fires or Heating or other purposes.
GB124957A (en) 1918-06-04 1919-04-10 Frederick William Miller Improvement in Glass Moulding.
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5066493A (en) 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
TW225528B (el) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
AU5151093A (en) 1992-10-14 1994-05-09 Unichema Chemie Bv Process for the preparation of alkylglycosides
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
DE4301781C2 (de) 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
GB9325400D0 (en) 1993-12-11 1994-02-16 Sarll David P G Temperature recorder
JP3745772B2 (ja) * 1993-12-17 2006-02-15 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤として有用なラパマイシン誘導体
WO1995028156A1 (en) * 1994-04-14 1995-10-26 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
PT817775E (pt) 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
JP3226545B2 (ja) 1995-06-09 2001-11-05 ノバルティス・アクチエンゲゼルシャフト ラパマイシン誘導体
IL122855A (en) 1995-07-06 2004-08-31 Novartis Ag History of N-Phenyl (Alkyl) - 7H-Pyrolo [-3,2d] Pyrimidine - 4 Amine, their preparation and pharmaceutical preparations containing them
US5567831A (en) * 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE19544507B4 (de) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
CZ295468B6 (cs) 1996-04-12 2005-08-17 Warner-Lambert Company Polycyklické sloučeniny
US6362164B1 (en) * 1996-06-11 2002-03-26 Novartis Ag Combination of a somatostatin analogue and a rapamycin
ATE308527T1 (de) 1996-06-24 2005-11-15 Pfizer Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
WO1998009970A2 (en) 1996-09-09 1998-03-12 American Home Products Corporation Alkylated rapamycin derivatives
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9619631D0 (en) * 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US5985325A (en) 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6152347A (en) 1998-01-30 2000-11-28 Acco Brands, Inc. Vertical Stapler
MEP30008A (en) 1998-03-26 2010-10-10 Astellas Pharma Inc Sustained release preparations
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
KR100406823B1 (ko) * 1998-04-27 2003-11-21 후지사와 야꾸힝 고교 가부시키가이샤 의약 조성물
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
EP1140173B2 (en) 1998-12-22 2013-04-03 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1165085E (pt) 1999-03-30 2006-10-31 Novartis Ag Derivados de ftalazina para tratar doencas inflamatorias
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
MXPA02001657A (es) 1999-08-18 2002-12-13 Wyeth Corp Esteres de 40-0-(2-hidroxi)etil-rapamicina hidrosolubles.
AU2292801A (en) 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
AU2623201A (en) 1999-12-30 2001-07-16 Kam W Leong Controlled delivery of therapeutic agents by insertable medical devices
WO2001051049A1 (en) * 2000-01-14 2001-07-19 The Trustees Of The University Of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
US6641811B1 (en) * 2000-02-10 2003-11-04 Cornell Research Foundation, Inc. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
GB0005257D0 (en) 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020013335A1 (en) 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
MXPA03001245A (es) 2000-08-11 2003-05-27 Wyeth Corp Metodo para el tratamiento del carcionma positivo para receptores de estrogeno.
AU2001287157A1 (en) * 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
US6696483B2 (en) 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
EP1330273B1 (en) 2000-10-31 2007-07-25 Cook Incorporated Coated implantable medical device
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
AU2002249826A1 (en) * 2000-12-22 2002-07-30 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
AU2002250968C1 (en) 2001-02-19 2018-01-04 Novartis Ag Cancer treatment
CN1309421C (zh) 2001-04-06 2007-04-11 惠氏公司 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合
MXPA03010907A (es) * 2001-06-01 2004-02-17 Wyeth Corp Combinaciones antineoplasicas.
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7488313B2 (en) 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
JP2003330447A (ja) 2002-05-15 2003-11-19 Mitsubishi Electric Corp 画像処理装置
NO20220050A1 (no) 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
EP2726140B1 (en) 2011-07-01 2020-12-16 Coloplast A/S A catheter with a balloon
EP2606816A1 (en) 2011-12-22 2013-06-26 Koninklijke Philips Electronics N.V. A method and system for providing an indication as to the amount of milk remaining in a breast during lactation

Also Published As

Publication number Publication date
NO20150413L (no) 2003-10-17
RU2003127391A (ru) 2005-03-27
LTPA2019511I1 (lt) 2019-06-25
NO20033651L (no) 2003-10-17
TWI334350B (en) 2010-12-11
JP2014208657A (ja) 2014-11-06
HK1250018B (en) 2020-04-17
HK1197723A1 (en) 2015-02-13
MX368013B (es) 2019-09-13
WO2002066019A2 (en) 2002-08-29
JP2014177469A (ja) 2014-09-25
RU2018127821A (ru) 2020-01-30
CZ309178B6 (cs) 2022-04-20
CY1121715T1 (el) 2020-05-29
LT3143995T (lt) 2019-01-25
JP2004525899A (ja) 2004-08-26
EP3345602B1 (en) 2022-04-06
EP3143995A1 (en) 2017-03-22
CZ307940B6 (cs) 2019-09-04
CN104083365A (zh) 2014-10-08
PL414997A1 (pl) 2016-02-29
NO2015010I1 (no) 2015-03-30
CY2020005I1 (el) 2020-05-29
IL229156A0 (en) 2013-12-31
CY1121314T1 (el) 2020-05-29
CA2860306A1 (en) 2002-08-29
RU2018121314A3 (el) 2021-10-06
SI2269603T1 (sl) 2015-08-31
JP5775022B2 (ja) 2015-09-09
CY2016047I2 (el) 2017-04-05
PT2762140T (pt) 2017-07-04
JP5873128B2 (ja) 2016-03-01
CY2019043I1 (el) 2020-05-29
CZ200591A3 (cs) 2019-01-23
BR0207378A (pt) 2004-06-15
IL220095A0 (en) 2012-07-31
HUP0303271A3 (en) 2010-09-28
EP2269603B1 (en) 2015-05-20
JP2015145411A (ja) 2015-08-13
CZ307637B6 (cs) 2019-01-23
NO336110B1 (no) 2015-05-18
JP2018100281A (ja) 2018-06-28
US8436010B2 (en) 2013-05-07
EP3406249A1 (en) 2018-11-28
IL250676B (en) 2018-06-28
DK3342411T3 (da) 2019-09-02
RU2322981C2 (ru) 2008-04-27
LTPA2019521I1 (lt) 2019-12-10
RU2665138C2 (ru) 2018-08-28
LTPA2016035I1 (lt) 2016-12-27
CA2438504A1 (en) 2002-08-29
ES2543383T3 (es) 2015-08-18
SK288546B6 (sk) 2018-03-05
RU2005105664A (ru) 2006-08-10
DK2269603T3 (en) 2015-08-24
SK10382003A3 (sk) 2004-03-02
IL229157A0 (en) 2013-12-31
JP2012184238A (ja) 2012-09-27
IL220095A (en) 2017-05-29
US20120214774A1 (en) 2012-08-23
JP2018100282A (ja) 2018-06-28
JP2014193901A (ja) 2014-10-09
SI2762140T1 (sl) 2017-07-31
CN104116738A (zh) 2014-10-29
JP2018168188A (ja) 2018-11-01
RU2445093C2 (ru) 2012-03-20
DK2762140T3 (en) 2017-07-10
IL220096A (en) 2015-10-29
CA2860306C (en) 2018-04-17
IL229160B (en) 2018-08-30
IL229160A0 (en) 2013-12-31
JP2007284454A (ja) 2007-11-01
NO334646B1 (no) 2014-05-05
RU2011138835A (ru) 2013-03-27
LT3351246T (lt) 2019-07-10
IL251270A0 (en) 2017-06-29
US20040147541A1 (en) 2004-07-29
NO20131544L (no) 2003-10-17
PL414996A1 (pl) 2016-02-29
IL229156A (en) 2017-02-28
NO20131546L (no) 2003-10-17
LU93320I2 (fr) 2017-01-30
PL363918A1 (pl) 2004-11-29
TW200626151A (en) 2006-08-01
KR100695846B1 (ko) 2007-03-19
PT2269603E (pt) 2015-09-09
LUC00122I1 (el) 2019-06-06
LT2762140T (lt) 2017-06-26
JP6349475B2 (ja) 2018-06-27
AU2002250968C1 (en) 2018-01-04
HK1250336B (en) 2020-02-07
NO333105B1 (no) 2013-03-04
NO20150831A1 (no) 2015-06-24
CZ2010473A3 (el) 2004-01-14
IL229159A0 (en) 2013-12-31
EP2764865A2 (en) 2014-08-13
US8877771B2 (en) 2014-11-04
EP3143995B1 (en) 2018-12-05
IL202155A (en) 2013-04-30
NO20190290A1 (no) 2003-10-17
RU2006140514A (ru) 2008-05-27
AU2002250968B2 (en) 2006-01-12
CY2016047I1 (el) 2017-04-05
EP2783686B1 (en) 2017-06-21
CN1679559A (zh) 2005-10-12
JP6310970B2 (ja) 2018-04-11
IL229158A0 (en) 2013-12-31
LUC00122I2 (el) 2019-12-24
US20130253000A1 (en) 2013-09-26
LTC2269604I2 (lt) 2020-01-27
SI3143995T1 (sl) 2019-02-28
JP6904640B2 (ja) 2021-07-21
US8778962B2 (en) 2014-07-15
HK1146247A1 (en) 2011-05-27
NO20130045L (no) 2003-10-17
CY1121983T1 (el) 2020-05-29
PL415000A1 (pl) 2016-02-29
EP3342411A1 (en) 2018-07-04
JP5879391B2 (ja) 2016-03-08
EP3351246A1 (en) 2018-07-25
EP3351246B1 (en) 2019-05-22
EP2764865A3 (en) 2014-10-01
DK3143995T3 (en) 2019-01-28
IL259724A (en) 2018-08-30
ES2600304T3 (es) 2017-02-08
NO20131547L (no) 2003-10-17
US20130244951A1 (en) 2013-09-19
DK2269604T3 (en) 2016-11-14
NO340553B1 (no) 2017-05-08
ES2640787T3 (es) 2017-11-06
MXPA03007418A (es) 2003-11-18
CN1296043C (zh) 2007-01-24
HK1198946A1 (en) 2015-06-19
NO339240B1 (no) 2016-11-21
RU2325906C2 (ru) 2008-06-10
CY1118316T1 (el) 2017-04-05
WO2002066019A3 (en) 2002-10-24
PL409579A1 (pl) 2015-03-02
CZ20032209A3 (cs) 2004-01-14
NO343599B1 (no) 2019-04-08
EP2783686A1 (en) 2014-10-01
JP2020143134A (ja) 2020-09-10
NO336581B1 (no) 2015-09-28
JP6383814B2 (ja) 2018-08-29
CY1119029T1 (el) 2018-01-10
ES2921798T3 (es) 2022-08-31
LU92880I2 (fr) 2016-11-17
PT3342411T (pt) 2019-09-19
SI2269604T1 (sl) 2016-11-30
CA2438504C (en) 2016-02-16
SK288524B6 (sk) 2018-01-04
IL259724B (en) 2021-12-01
EP2762140B1 (en) 2017-03-22
EP2269604A1 (en) 2011-01-05
IL229158A (en) 2017-03-30
NO20033651D0 (no) 2003-08-18
EP3345602A1 (en) 2018-07-11
CZ2018211A3 (el) 2004-01-14
ES2744377T3 (es) 2020-02-24
CN1551767A (zh) 2004-12-01
CY2015044I2 (el) 2017-03-15
SK902019A3 (el) 2004-03-02
CA2994779A1 (en) 2002-08-29
PT2269604T (pt) 2016-11-04
NO20161348A1 (no) 2016-08-24
JP2017081979A (ja) 2017-05-18
SK288545B6 (sk) 2018-03-05
PL231418B1 (pl) 2019-02-28
NO20120451L (no) 2003-10-17
EP3143995B2 (en) 2025-01-15
HUP0303271A2 (hu) 2004-01-28
CZ309247B6 (cs) 2022-06-22
PT3351246T (pt) 2019-06-07
NO335134B1 (no) 2014-09-22
KR20040007451A (ko) 2004-01-24
KR20070102762A (ko) 2007-10-19
NO20150895L (no) 2003-10-17
SI3351246T1 (sl) 2019-08-30
JP6333766B2 (ja) 2018-05-30
EP3342411B1 (en) 2019-08-21
IL220096A0 (en) 2012-07-31
RU2659725C2 (ru) 2018-07-03
RU2013119705A (ru) 2014-11-10
RU2018121314A (ru) 2019-12-10
RU2483727C1 (ru) 2013-06-10
KR100695846B9 (ko) 2021-09-30
IL251270B (en) 2018-06-28
SK288630B6 (sk) 2019-01-08
JP6349474B2 (ja) 2018-06-27
SI3342411T1 (sl) 2019-10-30
NO336428B1 (no) 2015-08-17
MX2019010879A (es) 2019-12-16
NO340924B1 (no) 2017-07-17
US20120283285A1 (en) 2012-11-08
US20130059877A1 (en) 2013-03-07
CA2994779C (en) 2020-08-25
EP2269604B1 (en) 2016-07-27
LT2269604T (lt) 2016-11-10
NO20170803A1 (no) 2003-10-17
US8410131B2 (en) 2013-04-02
EP1363627A2 (en) 2003-11-26
LTPA2020503I1 (lt) 2020-03-10
LT3342411T (lt) 2019-09-25
US20140105895A1 (en) 2014-04-17
SK288834B6 (sk) 2021-03-10
PT3143995T (pt) 2019-01-17
ES2728739T3 (es) 2019-10-28
CZ303611B6 (cs) 2013-01-09
ES2705016T3 (es) 2019-03-21
CY2019030I1 (el) 2020-05-29
NO20131545L (no) 2003-10-17
EP2762140A1 (en) 2014-08-06
CY2015044I1 (el) 2017-03-15
IL157425A0 (en) 2004-03-28
EP3351246B8 (en) 2019-09-18
US20160303092A1 (en) 2016-10-20
US20130287769A1 (en) 2013-10-31
JP2016222705A (ja) 2016-12-28
PT3345602T (pt) 2022-07-04
CN104274442A (zh) 2015-01-14
DK3351246T3 (da) 2019-06-03
NZ527692A (en) 2005-05-27
NO336208B1 (no) 2015-06-15
CZ2019248A3 (cs) 2004-01-14
EP2783686A8 (en) 2015-03-04
JP6349476B2 (ja) 2018-06-27
KR20050095906A (ko) 2005-10-04
US20130296359A1 (en) 2013-11-07
CY1116616T1 (el) 2017-03-15
RU2013143306A (ru) 2015-03-27
IL202155A0 (en) 2010-06-16
ES2629317T3 (es) 2017-08-08
HK1250019A1 (en) 2018-11-23
HK1146245A1 (en) 2011-05-27
IL157425A (en) 2013-10-31
EP2269603A1 (en) 2011-01-05
JP2018100283A (ja) 2018-06-28
IL250676A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
CY2019030I1 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
IL164599A0 (en) Combination therapy for the treatment of cancer
CY2015003I1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
HUP0500424A3 (en) Combination therapy for the treatment of cancer
NO20033205D0 (no) Terapeutiske kromanforbindelser
SI1487828T1 (sl) Morfolinil-sečninski derivati za uporabo pri zdravljenu vnetnih bolezni
IL175535A (en) Compositions for treatment of neurodegenerative diseases
DK1553950T3 (da) Terapeutisk behandling
NO20043445L (no) Kombinasjonsterapi for behandling av bakterielle infeksjoner
NO20033341D0 (no) Metoder for administrering av epothilone-analoger for behandling av kreft
DE60328516D1 (de) Thia-epothilon derivate zur krebsbehandlung
NO20063114L (no) Enoxaparin for behandling av cancer
NO20042166L (no) Kombinasjonsterapi for behandling av sykdom
NO20042542L (no) Anvendelse av ascomycin for behandling av blefarit
SI1537116T1 (sl) Pirazolopirimidini primerni za zdravljenje rakavih bolezni
HK1065929A (en) Combination therapy for the treatment of cancer
SE0100008D0 (sv) Therapeutic compounds
SE0100007D0 (sv) Therapeutic compounds